At the annual European congress of rheumatology meeting, The European League Against Rheumatism (EULAR), taking place in Amsterdam on June 13th-16th, leading investigators from United States, Israel, and Egypt will present new data on the 14-3-3η blood test. Several of these studies grow the body of evidence of 14-3-3η’s key role as an early diagnostic test that assists with rheumatoid arthritis (RA) patient management along the disease course. As a highlight, one study describes how 14-3-3η levels can assist with monitoring patients on Tofacitinib therapy. 14-3-3η is a modifiable marker of joint damage progression risk, which makes it ideal to track over time for the optimisation of RA treat-to-target strategies to improve clinical and radiographic outcomes. It is expected that 14-3-3η will have an increasingly important role in the management of RA patients across the entire disease continuum.
List of 14-3-3η EULAR 2018 Conference Proceedings
Decrease in 14-3-3 ETA Protein Levels is Correlated with Improvement of Clinical Disease Activity in Tofacitinib Treated Early Rheumatoid Arthritis Patients
Authors: Ora Shovman, Boris Gilburd, Abdulla Watad, Howard Amital, Pnina Langevitz, Nicola Luigi Bragazzi, Mohammad Adawi, Dolores Pérez, Miri Blank, Norma K. Biln, Anthony Marotta, Yehuda Shoenfeld
Abstract Number: AB0287
14-3-3 ETA Positivity is associated with Higher Rheumatoid Arthritis Disease Activity Measured by Multi-Biomarker Disease Activity Assay
Authors: Robert Chao, Mukund Das, Neha Purat, Petros Efthimiou
Abstract Number: AB0296
Clinical Significance of 14-3-3 ETA Protein Levels in Patients with Rheumatoid Arthritis
Authors: Ora Shovman, Boris Gilburd, Abdulla Watad, Howard Amital, Pnina Langevitz, Nicola Luigi Bragazzi, Mohammad Adawi, Dolores Pérez, Gil Bornstein , Merav Lidar , Miri Blank, Yosef Azuri, Norma K. Biln, Anthony Marotta, Yehuda Shoenfeld
Abstract Number: FRI0029
Assessment of Serum Levels of 14-3-3 ETA Protein in Rheumatoid Arthritis: Is it a Specific Marker for the Disease?
Authors: Mohsen Elshahaly, May Saleh, Hanaa Fahmy, Marihane Othman
Abstract Number: AB0273
Digital Technology Supercluster: Member Spotlight
The journey towards being truly patient-centric starts with a shared vision to ensure dynamic connectivity between healthcare providers and patients to keep people healthier longer and back to health sooner.
Augurex is working closely alongside supercluster members like Telus Health, Providence Healthcare, Microsoft and LifeLabs to advance patient-centric digital health solutions for people with Rheumatoid Arthritis. Click to learn more.
The 14-3-3η blood test is available in the United States through Labcorp and RDL Reference Laboratory. JOINTstat™ (14-3-3η) is CE marked and TGA approved for clinical use in Europe and Australia. In Canada, the test is available through LifeLabs and in Japan through Medical & Biological Laboratories (MBL).
For more information on the 14-3-3η test and Augurex Life Sciences Corp, visit www.augurex.com or www.jointstat.com.